Literature DB >> 25670929

The Influence of Clinical and Biological Factors on Transfusion-Associated Non-ABO Antigen Alloimmunization: Responders, Hyper-Responders, and Non-Responders.

Eric A Gehrie1, Christopher A Tormey2.   

Abstract

In the context of transfusion medicine, alloimmunization most often refers to the development of antibodies to non-ABO red blood cell (RBC) antigens following pregnancy, transfusion, or transplantation. The development of RBC alloantibodies can have important clinical consequences, particularly in patients who require chronic transfusions. It has been suggested that alloimmunization is more common in some clinical circumstances and patient populations than in others. As such, individuals that develop alloantibodies are frequently referred to as 'responders' in the medical literature. In contrast, individuals that do not develop alloantibodies despite repeated exposures to non-self blood group antigens have been referred to as 'non-responders'. The purpose of this article is to review the phenomenon of RBC alloimmunization in the context of responders and non-responders to: i) establish a basic framework for alloimmunization as reported across several diverse patient populations; ii) more fully explore literature reports which support the concept of responders/non-responders regarding blood group antigen alloimmunization; iii) summarize the mechanisms that have been shown to predispose an individual to alloimmunization to determine how these factors may differentiate 'responders' from 'non-responders'; and iv) briefly discuss some practical approaches to prevent alloimmunization in patients who may be prone to alloantibody development.

Entities:  

Keywords:  Alloimmunization; Blood group antigens; Immunohematology; Responders

Year:  2014        PMID: 25670929      PMCID: PMC4280450          DOI: 10.1159/000369109

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  84 in total

1.  Detection of anti-D in D- recipients transfused with D+ red blood cells.

Authors:  Mark H Yazer; Darrell J Triulzi
Journal:  Transfusion       Date:  2007-08-21       Impact factor: 3.157

2.  Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination.

Authors:  David Furman; Boris P Hejblum; Noah Simon; Vladimir Jojic; Cornelia L Dekker; Rodolphe Thiébaut; Robert J Tibshirani; Mark M Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-23       Impact factor: 11.205

3.  Red cell alloantibodies in patients with thalassemia.

Authors:  T Spanos; M Karageorga; V Ladis; J Peristeri; A Hatziliami; C Kattamis
Journal:  Vox Sang       Date:  1990       Impact factor: 2.144

4.  Experience with donors matched for minor blood group antigens in patients with sickle cell anemia who are receiving chronic transfusion therapy.

Authors:  D R Ambruso; J H Githens; R Alcorn; D J Dixon; L J Brown; W M Vaughn; T Hays
Journal:  Transfusion       Date:  1987 Jan-Feb       Impact factor: 3.157

5.  Primary immunization of Rh-negative volunteers.

Authors:  H H Gunson; F Stratton; D G Cooper; V I Rawlinson
Journal:  Br Med J       Date:  1970-03-07

6.  Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases.

Authors:  H Schonewille; H L Haak; A M van Zijl
Journal:  Transfusion       Date:  1999-07       Impact factor: 3.157

7.  Predicting the effect of transfusing only phenotype-matched RBCs to patients with sickle cell disease: theoretical and practical implications.

Authors:  Oswaldo Castro; S Gerald Sandler; Patricia Houston-Yu; Sohail Rana
Journal:  Transfusion       Date:  2002-06       Impact factor: 3.157

8.  Inflammation enhances consumption and presentation of transfused RBC antigens by dendritic cells.

Authors:  Jeanne E Hendrickson; Traci E Chadwick; John D Roback; Christopher D Hillyer; James C Zimring
Journal:  Blood       Date:  2007-06-25       Impact factor: 22.113

9.  Red cell alloimmunization in multitransfused HLA-typed patients.

Authors:  S G Brantley; G Ramsey
Journal:  Transfusion       Date:  1988 Sep-Oct       Impact factor: 3.157

10.  RBC alloimmunization and autoimmunization among transfusion-dependent Arab thalassemia patients.

Authors:  Reem Ameen; Salem Al-Shemmari; Salah Al-Humood; Rafiq I Chowdhury; Ohood Al-Eyaadi; Abdulaziz Al-Bashir
Journal:  Transfusion       Date:  2003-11       Impact factor: 3.157

View more
  12 in total

1.  Responder individuality in red blood cell alloimmunization.

Authors:  Christoph Gassner
Journal:  Transfus Med Hemother       Date:  2014-11-14       Impact factor: 3.747

2.  A locus on chromosome 5 shows African ancestry-limited association with alloimmunization in sickle cell disease.

Authors:  Lesedi M Williams; Zhihua Qi; Ken Batai; Stanley Hooker; Nancy J Hall; Roberto F Machado; Alice Chen; Sally Campbell-Lee; Yongtao Guan; Rick Kittles; Neil A Hanchard
Journal:  Blood Adv       Date:  2018-12-26

3.  Impact of azacitidine on red blood cell alloimmunisation in myelodysplastic syndrome.

Authors:  Sebastián Ortiz; Maria T Orero; Karla Javier; Carolina Villegas; Irene Luna; Pedro Pérez; Mónica Roig; María López; Sofía Costa; Félix Carbonell; Rosa Collado; David Ivars; Mariano Linares
Journal:  Blood Transfus       Date:  2016-06-24       Impact factor: 3.443

Review 4.  Medical and economic implications of strategies to prevent alloimmunization in sickle cell disease.

Authors:  Eric A Gehrie; Paul M Ness; Evan M Bloch; Seema Kacker; Aaron A R Tobian
Journal:  Transfusion       Date:  2017-06-26       Impact factor: 3.157

5.  Chronic inflammatory autoimmune disorders are a risk factor for red blood cell alloimmunization.

Authors:  Alex B Ryder; Jeanne E Hendrickson; Christopher A Tormey
Journal:  Br J Haematol       Date:  2015-10-12       Impact factor: 6.998

6.  Association of IL-6 C-572G Gene Polymorphism with Anti-E Production.

Authors:  Jeong-Shi Lin; Li-Hsuan Lee; Hsueng-Mei Liu; Ying-Ju Chen; Tzeon-Jye Chiou
Journal:  Transfus Med Hemother       Date:  2017-09-19       Impact factor: 3.747

7.  Pathophysiology of Alloimmunization.

Authors:  Rubiraida Molina-Aguilar; Soledad Gómez-Ruiz; Jorge Vela-Ojeda; Laura Arcelia Montiel-Cervantes; Elba Reyes-Maldonado
Journal:  Transfus Med Hemother       Date:  2019-08-06       Impact factor: 3.747

8.  Red blood cell minor antigen mismatches during chronic transfusion therapy for sickle cell anemia.

Authors:  Marianne E M Yee; Cassandra D Josephson; Anne M Winkler; Jennifer Webb; Naomi L C Luban; Traci Leong; Sean R Stowell; Ross M Fasano
Journal:  Transfusion       Date:  2017-08-24       Impact factor: 3.337

9.  Impact of antigenic exposures and role of molecular blood grouping in enhancing transfusion safety in chronically transfused thalassemics.

Authors:  Raj Nath Makroo; Soma Agrawal; Aakanksha Bhatia; Mohit Chowdhry; Uday Kumar Thakur
Journal:  Asian J Transfus Sci       Date:  2016 Jul-Dec

10.  A Conceptual Framework for Optimizing Blood Matching Strategies: Balancing Patient Complications Against Total Costs Incurred.

Authors:  Joost H J van Sambeeck; Puck D de Wit; Jessie Luken; Barbera Veldhuisen; Katja van den Hurk; Anne van Dongen; Maria M W Koopman; Marian G J van Kraaij; C Ellen van der Schoot; Henk Schonewille; Wim L A M de Kort; Mart P Janssen
Journal:  Front Med (Lausanne)       Date:  2018-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.